|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CCL5/CCR5 axis in human diseases and related treatments显示文摘To defense harmful stimuli or maintain the immune homeostasis, the body produces and recruits a superfamily of cytokines such as interleukins, interferons, chemokines etc. Among them, chemokines act as crucial regulators in defense systems. CCL5/CCR5 combination is known for facilitating inflammatory responses, as well as inducing the adhesion and migration of different T cell subsets in immune responses. In addition, recent studies have shown that the interaction between CCL5 and CCR5 is involved in various pathological processes including inflammation, chronic diseases, cancers as well as the infection of COVID-19. This review focuses on how CCL5/CCR5 axis participates in the pathological processes of different diseases and their relevant signaling pathways for the regulation of the axis. Moreover, we highlighted the gene therapy and chemotherapy studies for treating CCR5-related diseases, including the ongoing clinical trials. The barriers and perspectives for future application and translational research were also summarized. | Zhen Zeng Tianxia Lan Yuquan Wei Xiawei Wei | 2022 | Genes & Diseases2022，9，1： | 12 |
| 2 | The Hippo signalling pathway and its implications in human health and diseases显示文摘As an evolutionarily conserved signalling network,the Hippo pathway plays a crucial role in the regulation of numerous biological processes.Thus,substantial efforts have been made to understand the upstream signals that influence the activity of the Hippo pathway,as well as its physiological functions,such as cell proliferation and differentiation,organ growth,embryogenesis,and tissue regeneration/wound healing.However,dysregulation of the Hippo pathway can cause a variety of diseases,including cancer,eye diseases,cardiac diseases,pulmonary diseases,renal diseases,hepatic diseases,and immune dysfunction.Therefore,therapeutic strategies that target dysregulated Hippo components might be promising approaches for the treatment of a wide spectrum of diseases.Here,we review the key components and upstream signals of the Hippo pathway,as well as the critical physiological functions controlled by the Hippo pathway.Additionally,diseases associated with alterations in the Hippo pathway and potential therapies targeting Hippo components will be discussed. | Minyang Fu Yuan Hu Tianxia Lan Kun-Liang Guan Ting Luo Min Luo | 2022 | Signal Transduction and Targeted Therapy2022，7，12： | 5 |
| 3 | Multifunctional regulatory protein connective tissue growth factor (CTGF):A potential therapeutic target for diverse diseases显示文摘Connective tissue growth factor(CTGF),a multifunctional protein of the CCN family,regulates cell proliferation,differentiation,adhesion,and a variety of other biological processes.It is involved in the disease-related pathways such as the Hippo pathway,p53 and nuclear factor kappa-B(NF-κB)pathways and thus contributes to the developments of inflammation,fibrosis,cancer and other diseases as a downstream effector.Therefore,CTGF might be a potential therapeutic target for treating various diseases.In recent years,the research on the potential of CTGF in the treatment of diseases has also been paid more attention.Several drugs targeting CTGF(monoclonal antibodies FG3149 and FG3019)are being assessed by clinical or preclinical trials and have shown promising outcomes.In this review,the cellular events regulated by CTGF,and the relationships between CTGF and pathogenesis of diseases are systematically summarized.In addition,we highlight the current researches,focusing on the preclinical and clinical trials concerned with CTGF as the therapeutic target. | Minyang Fu Dandan Peng Tianxia Lan Yuquan Wei Xiawei Wei | 2022 | Acta Pharmaceutica Sinica B2022，12，4： | 5 |
| 4 | Author correction to‘Multifunctional regulatory protein connective tissue growth factor(CTGF):A potential therapeutic target for diverse diseases’[Acta pharmaceutica sinica B 12(2022)1740-1760]显示文摘The authors regret that there was an error in 7.Conclusion and prospect section of the article.The last paragraph of this section‘Under particular external…integrins interact with CT domain’is supposed to be the content of the figure legend(Fig.1).It is superfluous in this part and should be deleted.The revision does not affect any conclusions of this work. | Minyang Fu Dandan Peng Tianxia Lan Yuquan Wei Xiawei Wei | 2022 | Acta Pharmaceutica Sinica B2022，12，12： | 3 |
| 5 | Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment显示文摘For coronavirus disease 2019(COVID-19),caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),15–30%of patients are likely to develop COVID-19-related acute respiratory distress syndrome(ARDS).There are still few effective and well-understood therapies available.Novel variants and short-lasting immunity are posing challenges to vaccine efficacy,so finding antiviral and antiinflammatory treatments remains crucial.Here,tripterin(TP),a traditional Chinese medicine,was encapsulated into liposome(TP lipo)to investigate its antiviral and antiinflammatory effects in severe COVID-19.By using two severe COVID-19 models in human ACE2-transgenic(hACE2)mice,an analysis of TP lipo’s effects on pulmonary immune responses was conducted.Pulmonary pathological alterations and viral burden were reduced by TP lipo treatment.TP lipo inhibits SARS-CoV-2 replication and hyperinflammation in infected cells and mice,two crucial events in severe COVID-19 pathophysiology,it is a promising drug candidate to treat SARS-CoV-2-induced ARDS. | Haiying Que Weiqi Hong Tianxia Lan Hao Zeng Li Chen Dandan Wan Zhenfei Bi Wenyan Ren Min Luo Jingyun Yang Cai He Ailing Zhong Xiawei Wei | 2023 | Signal Transduction and Targeted Therapy2023，8，1： | 1 |
| 6 | Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants显示文摘The outbreak of coronavirus disease 2019(COVID-19)has posed great threats to global health and economy.Several effective vaccines are available now,but additional booster immunization is required to retain or increase the immune responses owing to waning immunity and the emergency of new variant strains.The deficiency of intramuscularly delivered vaccines to induce mucosal immunity urged the development of mucosal vaccines.Here,we developed an adjuvanted intranasal RBD vaccine and monitored its long-term immunogenicity against both wild-type and mutant strains of severe acute respiratory syndrome coronavirus-2(SARSCoV-2),including Omicron variants,in mice.Three-dose intranasal immunization with this vaccine induced and maintained high levels of neutralizing IgG antibodies in the sera for at least 1 year.Strong mucosal immunity was also provoked,including mucosal secretory IgA and lung-resident memory T cells(TRM).We also demonstrated that the long-term persistence of lung TRM cells is a consequence of local T-cell proliferation,rather than T-cell migration from lymph nodes.Our data suggested that the adjuvanted intranasal RBD vaccine is a promising vaccine candidate to establish robust,long-lasting,and broad protective immunity against SARS-CoV-2 both systemically and locally. | Hong Lei Aqu Alu Jingyun Yang Wenyan Ren Cai He Tianxia Lan Xuemei He Li Yang Jiong Li Zhenling Wang Xiangrong Song Wei Wang Guangwen Lu Xiawei Wei | 2022 | Signal Transduction and Targeted Therapy2022，7，6： | 1 |
| 7 | Omicron variant:a booster depending on infection histories显示文摘Recently,Reynold et al.published a study in Science1 showing that immune imprinting patterns might differentially influence immune responses against variants of concern(VOCs)of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).They also demonstrated that infection with B.1.1.529(Omicron variant)of SARS-CoV-2 confers only partial and transient protection against itself,resulting in frequent reinfections with Omicron in short time intervals. | Jiayu Wang Tianxia Lan Yuquan Wei Yoshimasa Tanaka | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 0 |
| 8 | Boosting with variant-matched vaccines: an opportunity to win the race against Omicron显示文摘Recently,Baoling Ying et al.published a study in Cell that investigated whether using BA.1-matched or historical mRNA vaccine as a booster could enhance the protection against Omicron infection.1 In this study,the team evaluated the anti-Omicron efficacies of these two types of vaccines as primary(two-dose)immunization series or thirddose boosters in mice,respectively(Fig.1).Many of the current outbreaks of COVID-19 around the world have been shown to be driven by the Omicron variant of SARSCoV-2.2 Although vaccination remains one of the most efficient approaches to containing the pandemic,amino acid substitutions,deletions,and insertions in the spike protein of the Omicron variant have substantially impaired the efficacy of most licensed vaccines.3 Hence,more effective vaccines or vaccination strategies against Omicron are urgently needed. | Jiayu Wang Tianxia Lan Qiu Sun | 2022 | Signal Transduction and Targeted Therapy2022，7，7： | 0 |
| 9 | Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis显示文摘A recent study published in Cell by Tyler N.Starr et al. presented a quantitative deep mutational scanning platform that allowed for the characterization of potential amino acid(AA)mutations to the SARS-CoV-2 receptor binding domain(RBD).The mutationphenotype maps provided in this work determined the influence of RBD expression and binding affinity to human cell-surface protein angiotensin-converting enzyme 2(ACE2)induced by fully random substitution for each AA of RBD.This work identified pivotal positions for virus binding and entry into cells,facilitating the development of countermeasures for COVID-19,such as vaccines. | Manni Wang Tianxia Lan Wei Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员